Tidbits. I believe that the nets will improve to some extent. Pharmonostics was charging us about 10.5% for their billing. On feb 28th 2015 their services were terminated. Scrc is now doing their own in house billing. The rate for billing seems outrageous. So if it is now being down at let's say 5% and i have no idea if thats the case or not that would be very good. We know in q1 2015 we did 400k in net income per the preliminary reports pr'ed to the markets. That was at 4%. If we apply the savings on the billing for q3 and q4 of 2015 and my guess is in the neighborhood we would be at 8% to 9% net. If we did 32m at 8% thats approx 2.4 net income fiscal year 2015. so .015 cents eps. ( again all speculation) at 10x that's .15 cents.


In q2 2015 initiatives were put in place for cost savings. The in house billing will help the overall #s imho.